Earnings Call · Q1 FY2026·2026-05-07

Q1 26EPS -8.82%·Rev n/aQ4 25EPS +11.76%·Rev n/aQ3 25EPS +13.95%·Rev n/aQ2 25EPS -4.55%·Rev n/a⚠ consensus missing

Amylyx Pharmaceuticals, Inc. AMLX

Lindsey Allen — Investor Relations or Communications

Justin Klee — Co-Chief Executive Officer

Dan Monahan — Role not explicitly stated, likely Commercial or Strategy Executive

Camille Bedrosian — Chief Medical Officer

James Frates — Chief Financial Officer

Joshua Cohen — Co-Chief Executive Officer

−5.4%1d on move date−5.0% vs SPY3d−7.3%5d−9.2%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AMLX calls or request research access.

More AMLX calls Browse calls Request research access